Search International and National Patent Collections

1. (WO2017041020) RENAL SELECTIVE INHIBITION OF CYTOCHROME P450 3A5

Pub. No.:    WO/2017/041020    International Application No.:    PCT/US2016/050239
Publication Date: Fri Mar 10 00:59:59 CET 2017 International Filing Date: Sat Sep 03 01:59:59 CEST 2016
IPC: C07K 14/80
C12N 15/11
C12N 15/113
Applicants: OREGON STATE UNIVERSITY
Inventors: IVERSEN, Patrick, L.
ANNALORA, Andrew, J.
Title: RENAL SELECTIVE INHIBITION OF CYTOCHROME P450 3A5
Abstract:
Compositions and methods for treating hypertension in a subject are provided, including administering an antisense oligomer effective to reduce expression of cytochrome P450 3A5 (CYP3A5) enzyme. The antisense oligomer includes phosphorodiamidate morpholino oligonucleotide (PMO), phosphorothioate 2'-0-methyl oligoribonucleotides (PSO), locked nucleic acid nucleotide, locked nucleic acid analog nucleotide, or another modified oligonucleotide backbone or nuclease-resistant backbone. The antisense oligomer is administered transdermally, subcutaneously, or orally, and optionally with a pharmaceutically acceptable carrier. In one embodiment, the antisense oligomer is an oligomer that is antisense to mRNAs that encode CYP3A5, for instance targeted at the AUG start site of the mRNAs that encode CYP3A5 or at a G4 structure within CYP3A5.